Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Melissa Schutten - Senior Scientist-Pathologist, Safety Assessment Pathology

Melissa Schutten

Senior Scientist-Pathologist, Safety Assessment Pathology

"Genentech provides a highly collaborative, fast-paced and scientifically rigorous environment that allows people to grow both personally and professionally. The scientists here are driven to succeed, innovative and, most importantly, curious."
10
Years at Genentech
20
Publications
3
Awards & Honors

I joined Genentech in 2010 after being on staff at the University of Minnesota, College of Veterinary Medicine, working in the field of comparative cancer biology and pathology. I have always been interested in animal models of human disease, particularly cancer, and was increasingly motivated to transition from basic research to translational research where I could focus my efforts on developing cancer drugs for human patients. I was drawn to Genentech by its reputation for being scientifically rigorous and collaborative, as well as being highly successful at bringing novel oncology therapies to market. I have been working in cancer drug research and development, mainly on the antibody drug conjugate platform, since 2010.

Featured Publication

Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1

2016. Tox. Path. Feb; 44(2) 267-78.

Zhong Y., Katavolos P., Nguyen T., Boggs J., Sambrone A., Kan D., Merchant M., Harstad E., Diaz D., Zak M., Costa M., Schutten, M.M.